Cytokinetics CYTK Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's cash & equivalents?
- Cytokinetics (CYTK) reported cash & equivalents of $129.84M in Q1 2026.
- How has Cytokinetics's cash & equivalents changed year-over-year?
- Cytokinetics's cash & equivalents increased by 76.2% year-over-year, from $73.68M to $129.84M.
- What is the long-term trend for Cytokinetics's cash & equivalents?
- Over 5 years (2020 to 2025), Cytokinetics's cash & equivalents has grown at a 8.1% compound annual growth rate (CAGR), from $82.99M to $122.52M.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid assets the company can access immediately.
- How do you interpret cash & equivalents?
- An increase suggests improved liquidity or recent capital raising, while a decrease indicates cash burn from operations or investment activities.
- How does cash & equivalents compare across companies?
- Biotech companies typically maintain high cash balances to fund multi-year clinical trials, often significantly higher than mature industrial peers.